Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Affinity Asset Advisors, LLC (CIK 1773195) reported $1.94B across 88 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: SPY ($130.1M, 6.72%), APGE ($108.2M, 5.59%), XENE ($97.4M, 5.03%), ERAS ($86.6M, 4.47%), INSM ($78.5M, 4.05%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | SPY | STATE STR SPDR S&P 500 ETF T | $130.1M | 6.72% | 200,000 | New |
| 2 | APGE | APOGEE THERAPEUTICS INC | $108.2M | 5.59% | 1.3M | Added |
| 3 | XENE | XENON PHARMACEUTICALS INC | $97.4M | 5.03% | 1.7M | Added |
| 4 | ERAS | ERASCA INC | $86.6M | 4.47% | 5.3M | Added |
| 5 | INSM | INSMED INC | $78.5M | 4.05% | 480,000 | Added |
| 6 | ROIV | ROIVANT SCIENCES LTD | $77.6M | 4.01% | 2.8M | Added |
| 7 | SYRE | SPYRE THERAPEUTICS INC | $64.5M | 3.33% | 1.3M | Trimmed |
| 8 | CNTA | CENTESSA PHARMACEUTICALS PLC | $55.6M | 2.87% | 1.4M | Added |
| 9 | PRAX | PRAXIS PRECISION MEDICINES I | $54.8M | 2.83% | 170,000 | Trimmed |
| 10 | ANAB | ANAPTYSBIO INC | $52.1M | 2.69% | 940,000 | Added |
| 11 | ALKS | ALKERMES PLC | $47.7M | 2.47% | 1.4M | Added |
| 12 | CYTK | CYTOKINETICS INC | $46.2M | 2.38% | 700,483 | Trimmed |
| 13 | ABVX | ABIVAX SA | $45.1M | 2.33% | 405,000 | Trimmed |
| 14 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $42.2M | 2.18% | 1.4M | Hold |
| 15 | ACLX | ARCELLX INC | $41.7M | 2.15% | 362,764 | Trimmed |
| 16 | MRNA | MODERNA INC | $40.6M | 2.10% | 800,000 | New |
| 17 | DNTH | DIANTHUS THERAPEUTICS INC | $33.6M | 1.73% | 400,000 | Added |
| 18 | NUVL | NUVALENT INC | $30.7M | 1.59% | 300,000 | Trimmed |
| 19 | TERN | TERNS PHARMACEUTICALS INC | $29.7M | 1.53% | 562,631 | Added |
| 20 | LXEO | LEXEO THERAPEUTICS INC | $29.0M | 1.50% | 5.1M | Added |
| 21 | MDGL | MADRIGAL PHARMACEUTICALS INC | $28.8M | 1.49% | 55,000 | Added |
| 22 | COGT | COGENT BIOSCIENCES INC | $28.9M | 1.49% | 750,000 | Added |
| 23 | STRO | SUTRO BIOPHARMA INC | $26.6M | 1.38% | 1.1M | Added |
| 24 | FBRX | FORTE BIOSCIENCES INC | $26.2M | 1.35% | 1.0M | Hold |
| 25 | ORKA | ORUKA THERAPEUTICS INC | $24.5M | 1.27% | 499,673 | Trimmed |
Source: SEC Form 13F filings · as of 2026-03-31